摘要
多发性硬化(MS)的疾病管理是一个长期过程,动态监测疾病活动和评估治疗反应,制定个体化MS全程管理方案成为临床所需。在传统检测方法基础上,分子生物标志物的探索和发展能更好地为MS个性化的早期疾病预、诊断、预后预测、动态评估疾病活动状态和治疗反应/安全性提供依据。MS生物标志物的检测样本主要来源于脑脊液和血液,虽然脑脊液检测特异性更高且应用更为成熟,但血液检测较脑脊液检测更为安全便捷,因此更适合用于MS疾病过程中的动态监测。同时,单分子阵列免疫分析等新型检测技术的应用能检测出血液中极低浓度的关键MS生物标志物,为研究血液生物标志物奠定了基础。文中聚焦分析血液动态检测的优势,对现有的MS血液生物标志物研究证据进行综述,探讨血液生物标志物检测在MS长期疾病管理中的临床应用价值,以期为临床实践和未来的研究提供参考。
Disease management of multiple sclerosis(MS) is a long-term process.Monitoring disease activity and assessing treatment response have become clinical needs for the development of individualized whole-course management of MS.Besides traditional measurements,the exploration and development of molecular biomarkers can better provide evidence for individualized early prediction of disease development,diagnosis,prognosis,and monitoring of disease activity and treatment response/safety of MS.MS biomarker testing samples are mainly derived from cerebrospinal fluid(CSF) and blood.Although CSF testing is mature and with high specificity,blood testing is more convenient and accessible than CSF testing,which makes it more suitable for monitoring MS disease management.Meanwhile,the application of some novel analytical platforms,such as single-molecule array technology,enables the detection of key MS biomarkers of extreme low concentration in the blood.It has been laying a foundation for MS blood biomarkers’ research.This review is focused on the advantage of blood biomarkers on monitoring disease activity and treatment response,reviewing the existing evidence of blood biomarkers for MS,summarizing the clinical values of blood biomarker testing in long-term management of MS,which will provide implications for clinical practice and future research.
作者
汪亮
张包静子
谭红梅
周磊
全超
WANG Liang;ZHANG BAO Jing-zi;TAN Hong-mei;ZHOU Lei;QUAN Chao(Department of Neurology,Huashan Hospital,Fudan University,The National Center for Neurological Disorders(NCND),Shanghai 200040,China)
出处
《中国临床神经科学》
2022年第4期427-435,共9页
Chinese Journal of Clinical Neurosciences
基金
百时美施贵宝公司。
